Article abstract
Nature Medicine 13, 1078 - 1085 (2007)
Published online: 19 August 2007 | doi:10.1038/nm1625
Lack of Fas antagonism by Met in human fatty liver disease
Chunbin Zou1, Jihong Ma1, Xue Wang1, Lida Guo1, Zhenqi Zhu1, John Stoops1, Amanda E Eaker1, Carla J Johnson1, Stephen Strom1, George K Michalopoulos1, Marie C DeFrances1 & Reza Zarnegar1
Abstract
Hepatocytes in fatty livers are hypersensitive to apoptosis and undergo escalated apoptotic activity via death receptor–mediated pathways, particularly that of Fas-FasL, causing hepatic injury that can eventually proceed to cirrhosis and end-stage liver disease. Here we report that the hepatocyte growth factor receptor, Met, plays an important part in preventing Fas-mediated apoptosis of hepatocytes by sequestering Fas. We also show that Fas antagonism by Met is abrogated in human fatty liver disease (FLD). Through structure-function studies, we found that a YLGA amino-acid motif located near the extracellular N terminus of the Met 
-subunit is necessary and sufficient to specifically bind the extracellular portion of Fas and to act as a potent FasL antagonist and inhibitor of Fas trimerization. Using mouse models of FLD, we show that synthetic YLGA peptide tempers hepatocyte apoptosis and liver damage and therefore has therapeutic potential.
- Department of Pathology, School of Medicine, University of Pittsburgh, S411A Biomedical Science Tower, 200 Lothrop Street, Pittsburgh, Pennsylvania 15261, USA.
Correspondence to: Reza Zarnegar1 e-mail: rezazar@pitt.edu
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Does increased body mass index with hepatic steatosis contribute to seroclearance of hepatitis B virus (HBV) surface antigen in chronic HBV infection?International Journal of Obesity Original Article
See all 15 matches for Research
